Cargando…

1086. Epidemiology, Risk Factors, and Effect of Antifungal Prophylaxis on Early Invasive Fungal Infection in Heart Transplant Recipients

BACKGROUND: Invasive fungal infection (IFI) in heart transplant recipients is associated with increased mortality and poor outcome. Reports have estimated the risk of 1-year IFI to be 3.4-8.6% with renal replacement therapy, delayed chest closure, and reoperation suggested as risk factors. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yetmar, Zachary A, Lahr, Brian, Brumble, Lisa, Banacloche, Juan Gea, Steidley, D Eric, Kushwaha, Sudhir, Beam, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777378/
http://dx.doi.org/10.1093/ofid/ofaa439.1272
_version_ 1783630888796422144
author Yetmar, Zachary A
Lahr, Brian
Brumble, Lisa
Banacloche, Juan Gea
Steidley, D Eric
Kushwaha, Sudhir
Beam, Elena
author_facet Yetmar, Zachary A
Lahr, Brian
Brumble, Lisa
Banacloche, Juan Gea
Steidley, D Eric
Kushwaha, Sudhir
Beam, Elena
author_sort Yetmar, Zachary A
collection PubMed
description BACKGROUND: Invasive fungal infection (IFI) in heart transplant recipients is associated with increased mortality and poor outcome. Reports have estimated the risk of 1-year IFI to be 3.4-8.6% with renal replacement therapy, delayed chest closure, and reoperation suggested as risk factors. However, the role of antifungal prophylaxis is unclear, though previous studies have suggested a reduced incidence of invasive Aspergillosis. The transplant program in Mayo Arizona provides 6 months of universal azole prophylaxis for Coccidioides, while Rochester and Florida only provide prophylaxis to high risk patients. We sought to define epidemiology and risk factors for 1-year IFI and determine the effect of antifungal prophylaxis. METHODS: We conducted a retrospective cohort study of patients undergoing single-organ heart transplantation at Mayo Rochester, Florida, or Arizona from January 2000 to March 2019. We identified baseline characteristics, details of transplant hospitalization such as need for renal replacement therapy, open chest, reoperation, and operative time, receipt of antifungal prophylaxis, and diagnosis of IFI. Multivariable Cox analysis was performed to identify risk factors of time to 1-year IFI. RESULTS: A total of 966 heart transplant recipients were identified with a median age of 56 years (IQR 47, 62) and 72% male. 444 patients received antifungal prophylaxis which included 32% fluconazole, 34% itraconazole, 18% voriconazole, 15% echinocandin, and < 1% amphotericin or posaconazole. Over 1-year follow-up, 62 patients developed IFI with a cumulative prevalence of 6.4%. The most common organisms were Aspergillus (50%) and Candida (27%). In a multivariable model, factors associated with 1-year IFI were post-transplant renal replacement therapy (HR 3.34, 95% CI 1.69-6.60; P < 0.001) and antifungal prophylaxis (HR 0.32, 95% CI 0.11-0.96; P=0.042). Operative time, recent hospitalization, open chest, and post-transplant mechanical circulatory support were not associated with 1-year IFI. CONCLUSION: Renal replacement therapy after transplantation is associated with 1-year IFI. Antifungal prophylaxis appears to be protective and further prospective study is warranted to verify this finding. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7777378
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77773782021-01-07 1086. Epidemiology, Risk Factors, and Effect of Antifungal Prophylaxis on Early Invasive Fungal Infection in Heart Transplant Recipients Yetmar, Zachary A Lahr, Brian Brumble, Lisa Banacloche, Juan Gea Steidley, D Eric Kushwaha, Sudhir Beam, Elena Open Forum Infect Dis Poster Abstracts BACKGROUND: Invasive fungal infection (IFI) in heart transplant recipients is associated with increased mortality and poor outcome. Reports have estimated the risk of 1-year IFI to be 3.4-8.6% with renal replacement therapy, delayed chest closure, and reoperation suggested as risk factors. However, the role of antifungal prophylaxis is unclear, though previous studies have suggested a reduced incidence of invasive Aspergillosis. The transplant program in Mayo Arizona provides 6 months of universal azole prophylaxis for Coccidioides, while Rochester and Florida only provide prophylaxis to high risk patients. We sought to define epidemiology and risk factors for 1-year IFI and determine the effect of antifungal prophylaxis. METHODS: We conducted a retrospective cohort study of patients undergoing single-organ heart transplantation at Mayo Rochester, Florida, or Arizona from January 2000 to March 2019. We identified baseline characteristics, details of transplant hospitalization such as need for renal replacement therapy, open chest, reoperation, and operative time, receipt of antifungal prophylaxis, and diagnosis of IFI. Multivariable Cox analysis was performed to identify risk factors of time to 1-year IFI. RESULTS: A total of 966 heart transplant recipients were identified with a median age of 56 years (IQR 47, 62) and 72% male. 444 patients received antifungal prophylaxis which included 32% fluconazole, 34% itraconazole, 18% voriconazole, 15% echinocandin, and < 1% amphotericin or posaconazole. Over 1-year follow-up, 62 patients developed IFI with a cumulative prevalence of 6.4%. The most common organisms were Aspergillus (50%) and Candida (27%). In a multivariable model, factors associated with 1-year IFI were post-transplant renal replacement therapy (HR 3.34, 95% CI 1.69-6.60; P < 0.001) and antifungal prophylaxis (HR 0.32, 95% CI 0.11-0.96; P=0.042). Operative time, recent hospitalization, open chest, and post-transplant mechanical circulatory support were not associated with 1-year IFI. CONCLUSION: Renal replacement therapy after transplantation is associated with 1-year IFI. Antifungal prophylaxis appears to be protective and further prospective study is warranted to verify this finding. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7777378/ http://dx.doi.org/10.1093/ofid/ofaa439.1272 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Yetmar, Zachary A
Lahr, Brian
Brumble, Lisa
Banacloche, Juan Gea
Steidley, D Eric
Kushwaha, Sudhir
Beam, Elena
1086. Epidemiology, Risk Factors, and Effect of Antifungal Prophylaxis on Early Invasive Fungal Infection in Heart Transplant Recipients
title 1086. Epidemiology, Risk Factors, and Effect of Antifungal Prophylaxis on Early Invasive Fungal Infection in Heart Transplant Recipients
title_full 1086. Epidemiology, Risk Factors, and Effect of Antifungal Prophylaxis on Early Invasive Fungal Infection in Heart Transplant Recipients
title_fullStr 1086. Epidemiology, Risk Factors, and Effect of Antifungal Prophylaxis on Early Invasive Fungal Infection in Heart Transplant Recipients
title_full_unstemmed 1086. Epidemiology, Risk Factors, and Effect of Antifungal Prophylaxis on Early Invasive Fungal Infection in Heart Transplant Recipients
title_short 1086. Epidemiology, Risk Factors, and Effect of Antifungal Prophylaxis on Early Invasive Fungal Infection in Heart Transplant Recipients
title_sort 1086. epidemiology, risk factors, and effect of antifungal prophylaxis on early invasive fungal infection in heart transplant recipients
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777378/
http://dx.doi.org/10.1093/ofid/ofaa439.1272
work_keys_str_mv AT yetmarzacharya 1086epidemiologyriskfactorsandeffectofantifungalprophylaxisonearlyinvasivefungalinfectioninhearttransplantrecipients
AT lahrbrian 1086epidemiologyriskfactorsandeffectofantifungalprophylaxisonearlyinvasivefungalinfectioninhearttransplantrecipients
AT brumblelisa 1086epidemiologyriskfactorsandeffectofantifungalprophylaxisonearlyinvasivefungalinfectioninhearttransplantrecipients
AT banaclochejuangea 1086epidemiologyriskfactorsandeffectofantifungalprophylaxisonearlyinvasivefungalinfectioninhearttransplantrecipients
AT steidleyderic 1086epidemiologyriskfactorsandeffectofantifungalprophylaxisonearlyinvasivefungalinfectioninhearttransplantrecipients
AT kushwahasudhir 1086epidemiologyriskfactorsandeffectofantifungalprophylaxisonearlyinvasivefungalinfectioninhearttransplantrecipients
AT beamelena 1086epidemiologyriskfactorsandeffectofantifungalprophylaxisonearlyinvasivefungalinfectioninhearttransplantrecipients